R. Katherine Alpaugh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
R. Katherine Alpaugh has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Kerry S. Campbell
Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, USA
96 shared publications - Alexander W. Macfarlane
Fox Chase Cancer Center, Temple University Health System Philadelphia Pennsylvania USA
95 shared publications - Matthew R. Zibelman
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
95 shared publications - Candice L. Schwebel
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
94 shared publications - Daniel M. Geynisman
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
94 shared publications - David I. Quinn
10Department of Medical Oncology, USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California
94 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 7: Representative IHC staining of additional PD and SD tumors in pre-treatment and post-treatment timepoint from additional patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 7: Representative IHC staining of additional PD and SD tumors in pre-treatment and post-treatment timepoint from additional patients.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 8: PD-L1 levels in tumor or tumor microenvironment does not associate with tumor progression or control.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 8: PD-L1 levels in tumor or tumor microenvironment does not associate with tumor progression or control.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 11: Peripheral immune cells are activated mid-treatment cycle.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 11: Peripheral immune cells are activated mid-treatment cycle.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 5: Overall tumor mutation burden and frequency of mutations in cancer-associated genes in UC tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 5: Overall tumor mutation burden and frequency of mutations in cancer-associated genes in UC tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 10: Peripheral immune cell dynamics induced by combination therapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 10: Peripheral immune cell dynamics induced by combination therapy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 1: Patient recruitment and sample collection overview.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 1: Patient recruitment and sample collection overview.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 12: HLA-DR and NKG2D abundance on peripheral lymphocytes associate with longer progression free survival.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 12: HLA-DR and NKG2D abundance on peripheral lymphocytes associate with longer progression free survival.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 4: Weak correlation of TE expression induction with DNA methylation change and viral mimicry activation.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 4: Weak correlation of TE expression induction with DNA methylation change and viral mimicry activation.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 9: CD8 infiltration in tumor is associated with survival.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 9: CD8 infiltration in tumor is associated with survival.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 6: Gene Set Enrichment Analysis reveals immune-related pathways discriminate PD and SD tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Supplementary Figure 6: Gene Set Enrichment Analysis reveals immune-related pathways discriminate PD and SD tumors.